Locoregional Treatment Outcomes After Multimodality Management of Inflammatory Breast Cancer

Ian J. Bristol, Wendy A. Woodward, Eric A. Strom, Massimo Cristofanilli, Delora Domain, S. Eva Singletary, George H. Perkins, Julia L. Oh, Tse Kuan Yu, Welela Terrefe, Aysegul A. Sahin, Kelly K. Hunt, Gabriel N. Hortobagyi, Thomas A. Buchholz*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

90 Scopus citations

Abstract

Purpose: The aims of this study were to determine outcomes for patients with inflammatory breast cancer (IBC) treated with multimodality therapy, to identify factors associated with locoregional recurrence, and to determine which patients may benefit from radiation dose escalation. Methods and Materials: We retrospectively reviewed 256 consecutive patients with nonmetastatic IBC treated at our institution between 1977 and 2004. Results: The 192 patients who were able to complete the planned course of chemotherapy, mastectomy, and postmastectomy radiation had significantly better outcomes than the 64 patients who did not. The respective 5-year outcome rates were: locoregional control (84% vs. 51%), distant metastasis-free survival (47% vs. 20%), and overall survival (51% vs. 24%) (p < 0.0001 for all comparisons). Univariate factors significantly associated with locoregional control in the patients who completed plan treatment were response to neoadjuvant chemotherapy, surgical margin status, number of involved lymph nodes, and use of taxanes. Increasing the total chest-wall dose of postmastectomy radiation from 60 Gy to 66 Gy significantly improved locoregional control for patients who experienced less than a partial response to chemotherapy, patients with positive, close, or unknown margins, and patients <45 years of age. Conclusions: Patients with IBC who are able to complete treatment with chemotherapy, mastectomy, and postmastectomy radiation have a high probability of locoregional control. Escalation of postmastectomy radiation dose to 66 Gy appears to benefit patients with disease that responds poorly to chemotherapy, those with positive, close, or unknown margin status, and those <45 years of age.

Original languageEnglish (US)
Pages (from-to)474-484
Number of pages11
JournalInternational Journal of Radiation Oncology Biology Physics
Volume72
Issue number2
DOIs
StatePublished - Oct 1 2008

Keywords

  • Inflammatory breast cancer
  • Locoregional therapy
  • Radiation dose

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'Locoregional Treatment Outcomes After Multimodality Management of Inflammatory Breast Cancer'. Together they form a unique fingerprint.

Cite this